Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Medexus's New Cancer Drug Secures Medicare Boost as Q1 Shows Early Commercial Success

Summary by stocktitan.net
Medexus's GRAFAPEX drug launch generates $3M revenue, wins Medicare add-on payment approval. Company projects $100M annual sales within 5 years. See detailed outlook.

2 Articles

stocktitan.netstocktitan.net

Medexus's New Cancer Drug Secures Medicare Boost as Q1 Shows Early Commercial Success

Medexus's GRAFAPEX drug launch generates $3M revenue, wins Medicare add-on payment approval. Company projects $100M annual sales within 5 years. See detailed outlook.

Read Full Article
JAMA NetworkJAMA Network

Trends in Launch Prices and Price Increases for Self-Administered Anticancer Drugs in Medicare

This study examines trends in launch prices and price increases for anticancer therapies covered under Medicare Part D and approved from 2010 to 2024.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

JAMA Network broke the news in on Tuesday, August 12, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Health icon

Health

Medicare icon

Medicare

United States icon

United States

News
For You
SearchBlindspotLocal